Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

CASIMERSEN vs RISDIPLAM: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

CASIMERSEN vs RISDIPLAM: Safety Overview

Metric CASIMERSEN RISDIPLAM
Total FAERS Reports 767 3,619
Deaths Reported 7 336
Death Rate 0.9% 9.3%
Hospitalizations 87 719
Average Patient Age 14.0 yrs 21.8 yrs
% Female Patients 0.4% 55.2%
FDA Approval Date Feb 25, 2021 Aug 7, 2020
Manufacturer Sarepta Therapeutics, Inc. Genentech, Inc.
Route N/A ORAL
Marketing Status Prescription Prescription